Financing round-up: HBOX Therapies, Resalis Therapeutics, Eluminex Biosciences, Angiodroid, VisionHealth
Germany: VisionHealth, a digital therapeutics company focused on enhancing inhaled treatment of chronic lung diseases, has closed a €3m pre-series A financing led by...
Australia: Kazia completes equity financing round
Kazia Therapeutics, an oncology-focused drug development company, has concluded an equity financing round totalling A$7.106m (US$4.78m) split A$4.5m raised from existing sophisticated and institutional...
Japan: Secondary follow-on of Amvis Holdings to raise JPY34.2bn
Two shareholders of Amvis Holdings, a fast-growing operator of hospice-type, disability nursing facilities, are selling 10 million shares to raise JPY34.2bn (US$255.1m) through a...
Israel: Teva to issue SLNs to fund tender offer
Teva Pharmaceutical Industries, a global leader in generic and innovative medicines, is issuing US$2.06bn (equivalent) of euro-denominated and US dollar-denominated sustainability-linked notes. Teva is...
Spex Capital launches €100m fund for early stage healthtech ventures
Digital health and med-tech investment firm Spex Capital has launched a new fund with a target size of €100m.
The Spex Venture HealthTech Fund is a closed-end...
UK: AstraZeneca issues €1.5bn fixed-rate bonds in two tranches
UK-headquartered Anglo-Swedish global biopharmaceutical company, AstraZeneca, has issued €1.5bn (US$1.6bn) in fixed-rate bonds split between two equally sized tranches over four and nine years.
The...
Italy: Panakès closes Purple Fund at €175m
Milan-based dedicated life science VC, Panakès Partners, has announced the final close of its Purple Fund at a total of €175m (US$186m). Panakès Purple...
Financing round-up: Synergia Medical, Macrolux Medical Technology, Terapet, NextKidney, Previa Medical
France: Previa Medical, a deeptech start-up developing predictive medical devices for alerting healthcare providers to the risk of potential complications, has raised €2.1m (US$2.2m)...
Denmark: Hemab closes US$135m Series B financing to support growth through 2025
Hemab Therapeutics, a clinical-stage biotechnology company developing the first prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, has closed an oversubscribed US$135m Series B financing....
New Zealand: Ryman raises NZ$542m from Institutional Entitlement Offer
NZX-listed Ryman Healthcare, which owns and operates 45 retirement villages in New Zealand and Australia, has completed the institutional component (Institutional Entitlement Offer) of...